Wilma Dormeyer

Title: Wilma Dormeyer: Innovator in Bi-specific Antibodies

Introduction

Wilma Dormeyer is a notable inventor based in Munich, Germany. She has made significant contributions to the field of bi-specific antibodies, holding 2 patents that focus on innovative therapeutic and diagnostic applications.

Latest Patents

Her latest patents include the development of bi-specific digoxigenin binding antibodies. This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin. The patent outlines methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and various uses thereof. Another significant patent involves a complex of bi-specific antibodies and digoxigenin conjugated to a therapeutic or diagnostic agent. This invention details complexes of bi-specific antibodies and antibody fragments against a target protein, along with a digoxigenin conjugated to a therapeutic or diagnostic agent, including methods for their production and applications in therapeutic or diagnostic settings.

Career Highlights

Wilma Dormeyer is currently associated with Hoffmann-La Roche Inc., where she continues to advance her research in the field of bi-specific antibodies. Her work has the potential to impact various therapeutic areas significantly.

Collaborations

She collaborates with esteemed colleagues, including Ulrich Brinkmann and Rebecca Croasdale, who contribute to her innovative projects and research endeavors.

Conclusion

Wilma Dormeyer stands out as a pioneering inventor in the realm of bi-specific antibodies, with her patents paving the way for advancements in therapeutic and diagnostic applications. Her contributions are vital to the ongoing evolution of medical science.